Iga Nephropathy
📧 Sign up to get email alerts when something new happens for Iga Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Results: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy [Phase 2]
Phase 2 randomized, double-blind, placebo-controlled crossover trial of atrasentan in IgA nephropathy completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Update: Atrasentan in Patients With IgA Nephropathy [Phase 3]
Phase 3 trial update for atrasentan in IgA nephropathy is active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) [Phase 1, Phase 2]
This document provides an update on the safety and tolerability of BION-1301 in healthy volunteers and adults with IgA nephropathy (IgAN) ac…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy [EARLY_Phase 1]
Clinical trial update for a Phase 1 study of CD19 CAR-γδ T cells in relapsed/refractory autoimmune nephropathy, targeting membranous nephrop…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN [Phase 3]
Phase 3 pediatric trial to assess the efficacy, pharmacokinetics, safety, and tolerability of iptacopan in children with primary IgA nephrop…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 [Phase 2]
Omeros' Phase 2 safety study of OMS721 in immunoglobulin A nephropathy, lupus nephritis, membranous nephropathy, and C3 glomerulopathy inclu…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. [Phase 2]
A Phase 2 study evaluating the efficacy and safety of HR19042 capsules for IgA nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Study of BHV-1400 in IgA Nephropathy [Phase 1]
This document announces an ongoing Phase 1 clinical trial evaluating BHV-1400 for IgA nephropathy, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment [Phase 1]
Phase 1 study of RG002C0106 injection in adults with normal renal function and mild-to-moderate renal impairment; the trial is not yet recru…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy [Phase 2]
Novartis conducted a Phase 2 randomized, double-blind, placebo-controlled crossover trial of atrasentan in patients with IgA nephropathy. Th…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy [Phase 1]
Takeda-sponsored Phase 1 trial of Mezagitamab in adults with primary IgA nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy [NA]
This clinical trial update notes a randomized controlled study evaluating Shenqi Yishen Granules for IgA nephropathy, with the trial not yet…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects [Phase 1]
Phase 1 trial comparing capsule and tablet formulations of HRS-5965 in healthy subjects has been completed.
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of LNP023 (iptacopan) in primary IgA nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 study of ARO-C3 from Arrowhead Pharmaceuticals in adults, including healthy volunteers a…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy [Phase 3]
A Phase 3 trial evaluating the safety and efficacy of OMS721 (narsoplimab) in IgA nephropathy has been terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Treatment of IgA Nephropathy According to Renal Lesions [Phase 3]
A Phase 3 clinical trial evaluating treatment strategies for IgA nephropathy according to renal lesions has completed; the update confirms c…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) [Phase 2]
Phase 2 study of ALXN2050 in proliferative lupus nephritis and IgA nephropathy was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects [Phase 1]
Phase 1 study evaluating the effect of food on the pharmacokinetics of HRS-5965 capsules in healthy subjects has completed. Conditions of in…
-
CLINICAL_TRIALS trial_result · 2025-05-04Clinical Trial Update: Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy [Phase 2]
A Phase 2 clinical trial evaluating alternate-day prednisone versus daily fish oil supplements for IgA nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: A Trial of HRS-5965 Tablets in Primary IgA Nephropathy [Phase 2]
Phase 2 trial of HRS-5965 for IgA nephropathy is active but not currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Relative Bioavailability Study of HR19042 in Healthy Subjects [Phase 1]
A Phase 1 relative bioavailability study of HR19042 in healthy subjects has completed. The trial evaluated pharmacokinetics and safety in he…
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept [Phase 2]
A phase 2 rollover trial update assessing long-term safety and efficacy of atacicept in IgA nephropathy, currently enrolling by invitation.
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: Rituximab and RASi in Patients with IgAN [Phase 4]
Phase 4 clinical trial evaluating rituximab plus renin-angiotensin system inhibitors in patients with IgA nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy [Phase 2]
A Phase 2 trial evaluating the efficacy and safety of SHR-2010 Injection in primary IgA nephropathy has been terminated.